Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 85 clinical trials
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with

  • 30 views
  • 15 Jun, 2022
  • 134 locations
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined

  • 1 views
  • 01 Jul, 2022
  • 283 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

letrozole
invasive breast cancer
gnrh
aromatase inhibitor
estrogen receptor
  • 2 views
  • 19 Feb, 2022
  • 55 locations
A Study of PF-06873600 in People With Cancer

therapy. The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle. Fulvestrant will be given every two weeks at the study clinic for the first

  • 69 views
  • 03 Jul, 2022
  • 35 locations
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.

primary tumor
core needle biopsy
letrozole
trastuzumab
estradiol
  • 17 views
  • 04 Feb, 2022
  • 47 locations
Study of Letrozole in Recurrent Gliomas

The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.

  • 14 views
  • 25 Feb, 2022
  • 1 location
Abemaciclib and Letrozole to Treat Endometrial Cancer

This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent

serum pregnancy test
neutrophil count
endometrial carcinoma
plain x-ray
letrozole
  • 0 views
  • 26 Mar, 2022
  • 26 locations
Letrozole in Patients With Hepatopulmonary Syndrome

The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.

hysterectomy
  • 0 views
  • 13 Apr, 2022
  • 2 locations
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation (CLC II)

This study evaluates the addition of clomiphene citrate (CC) to letrozole for the treatment of infertility in women with polycystic ovary syndrome across a course of two treatment cycles with

infertility
letrozole
ovulation induction
anovulation
anovulatory
  • 0 views
  • 24 Mar, 2022
  • 1 location
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers

  • 2 views
  • 15 Feb, 2022
  • 1 location